Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Johnson & Johnson
Femme et Homme Max 99 ans
Johnson & Johnson Consumer & Personal Products Worldwide, Division of Johnson & Johnson Consumer Companies, Inc
MAJ Il y a 4 ans
A four week study to evaluate how well a Medical Device mouth rinse treats gingivitis compared to a medicine mouth rinse
To determine the efficacy of Listerine®Advanced Defence Gum Treatment (a mouthwash classified as Class IIa medical device already on the market in the EU) on whole-mouth mean gingival bleeding index (...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ethicon Inc., a Johnson & Johnson Co
MAJ Il y a 4 ans
A study of the superior effect of EVARREST™ Fibrin Sealant Patch as compared to Standard Treatment in controlling bleeding during liver surgery
To evaluate the safety and hemostatic effectiveness of EVARREST Fibrin Sealant Patch versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
MAJ Il y a 4 ans
A Phase 3, Randomized, Double-Blind Study Of Ceftobiprole Medocaril Versus Vancomycin With Ceftazidime in The Treatment Of Complicated Skin And Skin Structure Infections
To demonstrate the noninferiority of ceftobiprole/placebo compared with Vancomycin/ceftazidime with respect to clinical cure rate in subjects with complicated skin and skin structure infections (cSSS...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
McNeil AB (Johnson & Johnson Consumer and Personal Products Worldwide, J&J CPPW)
MAJ Il y a 4 ans
Efficacy and safety following use of a novel nicotine replacement therapy. A multicenter, randomized, double blind, placebo-controlled, parallel group, 52-week study in smokers motivated to quit
To evaluate the efficacy of NMS versus placebo in smokers to achieve continuous abstinence from smoking from the week 2 visit until and including the week 6, week 24, and week 52 visits, respectively.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharamceutical Research & Development, L.L.C
MAJ Il y a 4 ans
Randomized, Double-Blind, Active-Control, Parallel Group, 90-Day Safety Study of CG5503 Immediate Release or Oxycodone Immediate Release in Subjects With Chronic Pain from Low Back Pain or Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the safety profile of CG5503 base IR 50 mg or 100 mg taken every 4 to 6 hours as needed over the long term exposure of 90 days
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharamceutical Research & Development, L.L.C
MAJ Il y a 4 ans
A Randomized, Double-Blind, Active- And Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety of Multiple Doses of CG5503 Immediate Release Formulation In Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease
The primary objective of this study is to determine the efficacy of CG5503 immediate-release (IR) using the sum of pain intensity difference (SPID) over 5 days compared with placebo, and to assess the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Taiwan Ltd
MAJ Il y a 4 ans
The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD) symptoms of pa...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharmaceutical Research & Development
MAJ Il y a 4 ans
A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment of anemia
The primary objective is to compare the safety with respect to the incidence of clinically relevant and objectively confirmed TVEs in 2 dosing regimens of epoetin alfa when used following guidelines f...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Johnson & Johnson
MAJ Il y a 4 ans
Johnson & Johnson CR014764 : Essai de phase 3 randomisé évaluant l’efficacité et la tolérance d’un traitement par trabectédine chez des patients ayant un cancer du sein. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de l’essai est d’évaluer l’efficacité et la tolérance d’un traitement par trabectédine chez des patients ayant un cancer du sein. Les patients sont répartis, en fonction du profil de leur ...
Pays
France
Organes
Sein
Spécialités
Thérapies Ciblées
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
MAJ Il y a 4 ans
A Study to Evaluate the Pharmacokinetics and Safety of Doripenem in Children and Adolescents with Cystic Fibrosis
To assess the pharmacokinetics of doripenem after a single 30 mg/kg doripenem 4-hour i.v. infusion administered to pediatric subjects 6 to 17 years of age, inclusive, with cystic fibrosis (CF). Safety...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Précédent
1
2
3
4
Suivant